ArticleFuture oncology (London, England)2025
A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited real-world evidence regarding patients with intermediate/poor-risk advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (NIVO+IPI) in England. This study aimed to describe characteristics, treatment patterns, and efficacy outcomes in these patients.
methodsA retrospective chart review of medical records in patients with aRCC receiving NIVO+IPI at any line of therapy between 5 April 2019 and 1 April 2022 in five sites across England was conducted. Data were analyzed descriptively overall, in patients with and without NIVO maintenance after NIVO+IPI initiation, and by prior nephrectomy status.
resultsIn total, 128 patients (mean age 60.7 years [standard deviation 10.1], 71.1% male) were eligible; most received first-line (1L) NIVO+IPI (n = 122, 95.3%). Median follow-up was 13.6 months (interquartile range [IQR] 7.1-25.0). Median progression-free survival and overall survival (OS) were 7.6 months (95% confidence interval [CI]: 5.6, 13.1) and 30.7 months (95% CI: 22.5, not reached), respectively. Median OS was not reached in patients who received NIVO+IPI plus NIVO maintenance and patients with prior nephrectomy.
conclusionPatients who received NIVO+IPI with NIVO maintenance and patients who had undergone prior nephrectomy experienced the most favorable survival outcomes, aligning with results from previous studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.